| Aktie | Ticker | Breite | GCS | 2026/Q1 | 2025/Q4 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 119.668.111 $ | +42.509.829 $ | +61,8 % | 5 | 106.710.558 $ | +106.710.558 $ | 6 | |||||
| Revolution Medicines, Inc. | RVMD | → 0 | Neutral | 80.617.722 $ | +8.901.499 $ | +12,4 % | 1 | 71.716.223 $ | +71.716.223 $ | 1 | |
| Oric Pharmaceuticals, Inc. | ORIC | → 0 | Schwach | 31.162.511 $ | +31.162.511 $ | 1 | |||||
| Protagonist Therapeutics, Inc | PTGX | → 0 | Neutral | 16.579.141 $ | +16.579.141 $ | 1 | |||||
| ArriVent BioPharma, Inc. | AVBP | → 0 | Schwach | 12.973.135 $ | +12.973.135 $ | 1 | |||||
| NovaBridge Biosciences | NBP | → 0 | Neutral | 5.566.815 $ | +3.919.179 $ | +237,9 % | 1 | 1.647.636 $ | +1.647.636 $ | 1 | |
| Cogent Biosciences, Inc. | COGT | → 0 | Neutral | 1.978.463 $ | -1.573.537 $ | -44,3 % | 1 | 3.552.000 $ | +3.552.000 $ | 1 | |
| Korro Bio, Inc. | KRRO | → 0 | Schwach | 342.600 $ | +100.177 $ | +41,3 % | 1 | 242.423 $ | +242.423 $ | 1 | |
| 119.668.111 $ | +42.509.829 $ | +61,8 % | 5 | 106.710.558 $ | +106.710.558 $ | 6 | |||||